IE810036L - Sustained release compositions - Google Patents
Sustained release compositionsInfo
- Publication number
- IE810036L IE810036L IE810036A IE3681A IE810036L IE 810036 L IE810036 L IE 810036L IE 810036 A IE810036 A IE 810036A IE 3681 A IE3681 A IE 3681A IE 810036 L IE810036 L IE 810036L
- Authority
- IE
- Ireland
- Prior art keywords
- amount
- milligrams
- release controlling
- agent
- controlling agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A sustained release pharmaceutical composition in table-t form comprises an effective amount of an orallyactive therapeutic agent, 0.8 to 1. 6% by weight of a release controlling agent and 1.0 to 7.5% by weight of an erosion promoting agent, the relative amounts of the components being such that a criticality factor calculated according to equation I lies in the range 20 to 450. Equation 1 is <IMG> I wherein CF is the criticality factor, CA is the. amount of therapeutic agent per tablet in milligrams divided by the amount of release controlling agent per tablet in milligrams and CS is the amount of erosion promoting agent per tablet in milligrams divided by the amount of release controlling agent per-tablet in milligrams, Suitable therapeutic agents include acetylsalicylic acid, ibuprofen and flurbiprofen. A preferred release controlling agent is cellulose acetate phthalate and a preferred erosion promoting agent is corn starch.
[CA1140466A]
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11143080A | 1980-01-11 | 1980-01-11 | |
US06/194,453 US4308251A (en) | 1980-01-11 | 1980-10-17 | Controlled release formulations of orally-active medicaments |
Publications (2)
Publication Number | Publication Date |
---|---|
IE810036L true IE810036L (en) | 1981-07-11 |
IE50806B1 IE50806B1 (en) | 1986-07-23 |
Family
ID=26808896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE36/81A IE50806B1 (en) | 1980-01-11 | 1981-01-09 | Pharmaceutical compositions |
Country Status (22)
Country | Link |
---|---|
JP (1) | JPS56103110A (en) |
AT (1) | AT374681B (en) |
AU (1) | AU542824B2 (en) |
BE (1) | BE886998A (en) |
CA (1) | CA1140466A (en) |
CH (1) | CH646604A5 (en) |
DE (1) | DE3100191A1 (en) |
DK (1) | DK6181A (en) |
ES (2) | ES8205353A1 (en) |
FI (1) | FI76927C (en) |
FR (1) | FR2473308B1 (en) |
GB (1) | GB2067072B (en) |
GR (1) | GR73843B (en) |
IE (1) | IE50806B1 (en) |
IN (1) | IN151913B (en) |
IT (1) | IT1221041B (en) |
LU (1) | LU83052A1 (en) |
NL (1) | NL8100037A (en) |
NO (1) | NO156153C (en) |
NZ (1) | NZ195933A (en) |
SE (1) | SE447450B (en) |
ZA (1) | ZA81136B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2496082A (en) * | 1947-05-24 | 1950-01-31 | Ashenfelter William | Scaffold structure |
IT1144911B (en) * | 1981-03-19 | 1986-10-29 | Pharmatec Spa | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING IBUPROFEN |
JPS59227817A (en) * | 1983-06-07 | 1984-12-21 | Toyo Jozo Co Ltd | Long-acting bredinin preparation for oral administration |
JPH0662404B2 (en) * | 1983-06-14 | 1994-08-17 | シンテックス・ファーマシユーテイカルズ・インターナシヨナル・リミテツド | Controlled-release naproxen and naproxen sodium tablets |
ZA836031B (en) * | 1983-08-16 | 1985-02-27 | Verex Lab | Constant release rate solid dosage theophylline formulation |
ZA836030B (en) * | 1983-08-16 | 1985-02-27 | Verex Lab | Constant order release solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions |
DE3486029T2 (en) * | 1983-10-14 | 1993-05-13 | Sumitomo Pharma | IFN PREPARATION WITH DELAYED DELIVERY FOR PARENTAL ADMINISTRATION. |
US4774091A (en) * | 1983-10-14 | 1988-09-27 | Sumitomo Pharmaceuticals Company, Ltd. | Long-term sustained-release preparation |
US4855134A (en) * | 1983-10-14 | 1989-08-08 | Sumitomo Pharmaceuticals Company, Limited | Sustained-release preparation |
US5385738A (en) * | 1983-10-14 | 1995-01-31 | Sumitomo Pharmaceuticals Company, Ltd. | Sustained-release injection |
EP0230647B1 (en) * | 1985-12-27 | 1993-03-31 | Sumitomo Pharmaceuticals Company, Limited | Method for producing a sustained release formulation |
GB8601204D0 (en) * | 1986-01-18 | 1986-02-19 | Boots Co Plc | Therapeutic agents |
US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
ZA881301B (en) * | 1987-02-27 | 1989-10-25 | Lilly Co Eli | Sustained release matrix formulations |
WO1997002019A1 (en) * | 1995-06-30 | 1997-01-23 | Baylor University | Polyester/carboxylic acid composite materials |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2953497A (en) * | 1953-06-03 | 1960-09-20 | Howard A Press | Therapeutic tablets |
NL128902C (en) * | 1960-06-06 | |||
US3577514A (en) * | 1968-06-10 | 1971-05-04 | Pfizer | Sustained release pharmaceutical tablets |
US3773920A (en) * | 1971-07-14 | 1973-11-20 | Nikken Chemicals Co Ltd | Sustained release medicinal composition |
US3906086A (en) * | 1971-07-19 | 1975-09-16 | Richard G Powers | Timed-release aspirin |
GB1500300A (en) * | 1975-01-06 | 1978-02-08 | Ciba Geigy Ag | Pharmaceutical preparation for the treatment of circulatory disorders |
JPS5411226A (en) * | 1977-06-24 | 1979-01-27 | Shin Etsu Chem Co Ltd | Disintegratable granule |
-
1980
- 1980-12-23 IN IN1418/CAL/80A patent/IN151913B/en unknown
- 1980-12-23 NZ NZ195933A patent/NZ195933A/en unknown
-
1981
- 1981-01-05 AU AU65976/81A patent/AU542824B2/en not_active Ceased
- 1981-01-06 FR FR8100087A patent/FR2473308B1/en not_active Expired
- 1981-01-07 NL NL8100037A patent/NL8100037A/en not_active Application Discontinuation
- 1981-01-07 DE DE19813100191 patent/DE3100191A1/en active Granted
- 1981-01-08 CH CH9281A patent/CH646604A5/en not_active IP Right Cessation
- 1981-01-08 GB GB8100522A patent/GB2067072B/en not_active Expired
- 1981-01-08 JP JP157881A patent/JPS56103110A/en active Pending
- 1981-01-08 ES ES498369A patent/ES8205353A1/en not_active Expired
- 1981-01-08 DK DK6181A patent/DK6181A/en not_active Application Discontinuation
- 1981-01-08 BE BE0/203426A patent/BE886998A/en unknown
- 1981-01-09 IT IT47537/81A patent/IT1221041B/en active
- 1981-01-09 ZA ZA00810136A patent/ZA81136B/en unknown
- 1981-01-09 NO NO810062A patent/NO156153C/en unknown
- 1981-01-09 FI FI810056A patent/FI76927C/en not_active IP Right Cessation
- 1981-01-09 LU LU83052A patent/LU83052A1/en unknown
- 1981-01-09 GR GR63828A patent/GR73843B/el unknown
- 1981-01-09 AT AT0005481A patent/AT374681B/en not_active IP Right Cessation
- 1981-01-09 CA CA000368219A patent/CA1140466A/en not_active Expired
- 1981-01-09 IE IE36/81A patent/IE50806B1/en unknown
- 1981-01-09 SE SE8100104A patent/SE447450B/en not_active IP Right Cessation
-
1982
- 1982-01-29 ES ES509179A patent/ES8301629A1/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
ZA81136B (en) | 1982-01-27 |
SE447450B (en) | 1986-11-17 |
GR73843B (en) | 1984-05-07 |
GB2067072B (en) | 1983-08-10 |
NO156153C (en) | 1987-08-05 |
FR2473308B1 (en) | 1985-07-19 |
CH646604A5 (en) | 1984-12-14 |
NZ195933A (en) | 1982-11-23 |
DK6181A (en) | 1981-07-12 |
IT1221041B (en) | 1990-06-21 |
NL8100037A (en) | 1981-08-03 |
DE3100191C2 (en) | 1988-09-01 |
IT8147537A0 (en) | 1981-01-09 |
FI76927B (en) | 1988-09-30 |
JPS56103110A (en) | 1981-08-18 |
AU6597681A (en) | 1981-07-16 |
NO810062L (en) | 1981-07-13 |
IN151913B (en) | 1983-09-03 |
ATA5481A (en) | 1983-10-15 |
BE886998A (en) | 1981-07-08 |
AU542824B2 (en) | 1985-03-14 |
ES509179A0 (en) | 1982-12-16 |
AT374681B (en) | 1984-05-25 |
LU83052A1 (en) | 1982-09-10 |
GB2067072A (en) | 1981-07-22 |
CA1140466A (en) | 1983-02-01 |
NO156153B (en) | 1987-04-27 |
FR2473308A1 (en) | 1981-07-17 |
ES498369A0 (en) | 1982-06-01 |
IE50806B1 (en) | 1986-07-23 |
SE8100104L (en) | 1981-07-12 |
FI76927C (en) | 1989-01-10 |
ES8301629A1 (en) | 1982-12-16 |
FI810056L (en) | 1981-07-12 |
ES8205353A1 (en) | 1982-06-01 |
DE3100191A1 (en) | 1981-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IE810036L (en) | Sustained release compositions | |
CA2009890A1 (en) | Valproic acid | |
JPS55153715A (en) | Prolonged granule of theophylline | |
IE791172L (en) | Pharmaceutical compositions containing urea | |
GR3031135T3 (en) | Compositions containing S(+)-Ibuprofen. | |
ES2110212T3 (en) | EFFERVESCENT PHARMACEUTICAL COMPOSITION CONTAINING IBUPROPHEN AND ITS PREPARATION PROCEDURE. | |
ES8502334A1 (en) | Elastase-containing composition permitting elastase to be absorbed in increased amount. | |
MY104010A (en) | Pharmaceutical compositions. | |
IE45439L (en) | Penicillanic acid derivatives | |
ES8605975A1 (en) | Controlled release liquid dosage formulations for pharmaceuticals. | |
IE781032L (en) | Pharmaceutical compositions | |
TW350772B (en) | Tablets with improved bioavailability of the active material clodronic acid | |
GB1353635A (en) | Coating composition for moist surfaces | |
AU1112395A (en) | Novel pharmaceutical composition for the preparation of a stable powder containing an active principle comprising an association of acetylsalicylic acid and metoclopramide | |
IL65922A (en) | Preparation of apovincaminic acid esters,certain novel optically active trans-derivatives thereof and pharmaceutical compositions containing them | |
US3035987A (en) | Method of increasing the water vapor porosity of fat materials | |
IL102949A0 (en) | Substituted mandelic acid derivatives,their preparation and pharmaceutical compositions containing them | |
GB1381426A (en) | Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents | |
ES8304992A1 (en) | Bis-esters of alkanediols, pharmaceutical compositions thereof and intermediates therefor. | |
CA2078885A1 (en) | Pharmaceutical compositions containing amethocaine | |
JPS5750914A (en) | Betamethasone external pharmaceutical | |
ATE16100T1 (en) | ESTERS OF 1-METHYL-5-P-TOLUOYLPYRROLYL-2ACETIC ACID WITH ANTI-INFLAMMATORY, MUCOLYTIC AND ANTI-TUSSIVE PROPERTIES, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
DE3166825D1 (en) | Process for manufacture of a coated acetylsalicylic-acid formulation | |
GB1388856A (en) | Fibrinolytic activators comprising derivatives of phenyl benzoate | |
AU645205B2 (en) | Stabilized solid dosage forms of choline metal carboxymethylcellulose salicylate compositions |